UA115455C2 - Спосіб одержання сполук для застосування при лікуванні раку - Google Patents

Спосіб одержання сполук для застосування при лікуванні раку

Info

Publication number
UA115455C2
UA115455C2 UAA201504532A UAA201504532A UA115455C2 UA 115455 C2 UA115455 C2 UA 115455C2 UA A201504532 A UAA201504532 A UA A201504532A UA A201504532 A UAA201504532 A UA A201504532A UA 115455 C2 UA115455 C2 UA 115455C2
Authority
UA
Ukraine
Prior art keywords
cancer
treatment
novel process
making compounds
making
Prior art date
Application number
UAA201504532A
Other languages
English (en)
Inventor
Срірам Наганатхан
Натхан Гуз
Меттью Пфайффер
К. Грегорі Сауелл
Трейсі Бостік
Джейсон Ян
Аміт Срівастава
Original Assignee
Екселіксіс, Інк.
Дженентек, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Екселіксіс, Інк., Дженентек, Інк. filed Critical Екселіксіс, Інк.
Publication of UA115455C2 publication Critical patent/UA115455C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

У даному документі розкрито спосіб отримання сполуки формули І EMBED ISISServer (I). Сполука формули І являє собою інгібітор МЕK і, таким чином, може бути застосована для лікування раку.
UAA201504532A 2012-10-12 2013-10-14 Спосіб одержання сполук для застосування при лікуванні раку UA115455C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
UA115455C2 true UA115455C2 (uk) 2017-11-10

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201504532A UA115455C2 (uk) 2012-10-12 2013-10-14 Спосіб одержання сполук для застосування при лікуванні раку

Country Status (31)

Country Link
US (4) US9771347B2 (uk)
EP (1) EP2909188B1 (uk)
JP (2) JP6300042B2 (uk)
KR (1) KR102204520B1 (uk)
CN (2) CN104837826B (uk)
AU (1) AU2013328929B2 (uk)
BR (1) BR112015008113B1 (uk)
CA (1) CA2889466C (uk)
CL (1) CL2015000926A1 (uk)
CR (2) CR20200237A (uk)
EA (1) EA030613B1 (uk)
ES (1) ES2671502T3 (uk)
GE (1) GEP201706690B (uk)
HK (2) HK1213567A1 (uk)
HR (1) HRP20180670T1 (uk)
IL (1) IL238116B (uk)
IN (1) IN2015DN03928A (uk)
MA (1) MA38085B1 (uk)
MX (2) MX2015004660A (uk)
MY (1) MY186549A (uk)
NZ (1) NZ706723A (uk)
PE (3) PE20191818A1 (uk)
PH (1) PH12015500785A1 (uk)
PL (1) PL2909188T3 (uk)
SA (1) SA515360271B1 (uk)
SG (1) SG11201502795VA (uk)
SI (1) SI2909188T1 (uk)
TR (1) TR201807861T4 (uk)
UA (1) UA115455C2 (uk)
WO (1) WO2014059422A1 (uk)
ZA (1) ZA201502349B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013328929B2 (en) 2012-10-12 2018-01-04 Exelixis, Inc. Novel process for making compounds for use in the treatment of cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
TWI804919B (zh) 2015-06-30 2023-06-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
EP3496752B1 (en) 2016-08-12 2022-05-18 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
BR112019005815A2 (pt) 2016-09-29 2019-06-25 Genentech Inc métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
KR20230156731A (ko) 2021-03-09 2023-11-14 제넨테크, 인크. 뇌암 치료에 이용하기 위한 벨바라페닙
WO2022216719A1 (en) 2021-04-06 2022-10-13 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
EP0754684A4 (en) 1994-04-01 1998-05-13 Shionogi & Co OXIME DERIVATIVES AND BACTERICIDE CONTAINING IT AS ACTIVE INGREDIENTS
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6251943B1 (en) 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
EP0993437B1 (en) * 1997-07-01 2006-11-08 Warner-Lambert Company Llc 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
DE69826662T2 (de) 1997-07-01 2005-02-17 Warner-Lambert Co. Llc 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
IL143231A0 (en) 1998-12-15 2002-04-21 Warner Lambert Co Use of a mek inhibitors for preventing transplant rejection
WO2000035436A2 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
AU2203900A (en) 1998-12-22 2000-07-12 Warner-Lambert Company Combination chemotherapy
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
ATE292462T1 (de) 1999-01-07 2005-04-15 Warner Lambert Co Behandlung von asthma anhand von mek-inhibitoren
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
IL144215A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
WO2000042003A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
CZ20012498A3 (cs) 1999-01-13 2002-08-14 Warner-Lambert Company Benzoheterocyklické sloučeniny a jejich pouľití jako inhibitorů MEK
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
IL147617A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
ES2208364T3 (es) 1999-07-16 2004-06-16 Warner-Lambert Company Llc Procedimiento para tratar dolor cronico usando inhibidores de mek.
CN1373660A (zh) 1999-07-16 2002-10-09 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
WO2001019788A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
BRPI0112584B8 (pt) 2000-07-19 2021-05-25 Warner Lambert Co ésteres oxigenados de derivados de ácido benzidroxâmico de 4-iodofenilamino, composição farmacêutica e combinação
PL360699A1 (en) * 2000-08-25 2004-09-20 Warner-Lambert Company Llc. Process for making n-aryl-anthranilic acids and their derivatives
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
JP2005507411A (ja) 2001-10-31 2005-03-17 ファイザー・プロダクツ・インク 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。
WO2003062191A1 (en) 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
RU2300528C2 (ru) 2002-03-13 2007-06-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
EP2130536B1 (en) 2002-03-13 2013-05-08 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
WO2003103590A2 (en) 2002-06-11 2003-12-18 Merck & Co., Inc. (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
PL214032B1 (pl) 2003-03-03 2013-06-28 Array Biopharma Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05013227A (es) 2003-06-20 2006-03-09 Celltech R&D Ltd Derivados de tienopiridona como inhibidores de cinasa.
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
JP4896717B2 (ja) 2003-07-24 2012-03-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｎ−メチル−置換ベンゾアミダゾール
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
BRPI0416692A (pt) 2003-11-19 2007-01-30 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de emprego destes
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4527729B2 (ja) 2003-12-08 2010-08-18 エフ．ホフマン−ラ ロシュ アーゲー 新規チアゾール誘導体
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
JP5214971B2 (ja) * 2004-10-20 2013-06-19 メルク セローノ ソシエテ アノニム ３−アリルアミノピペリジン誘導体
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EA032466B1 (ru) * 2005-10-07 2019-05-31 Экселиксис, Инк. Способы получения ингибиторов mek
JP2010500994A (ja) 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
CN111643496A (zh) 2006-12-14 2020-09-11 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
AU2013328929B2 (en) 2012-10-12 2018-01-04 Exelixis, Inc. Novel process for making compounds for use in the treatment of cancer
JP6451652B2 (ja) 2014-02-07 2019-01-16 住友化学株式会社 （ｒ）−１，１，３−トリメチル−４−アミノインダンの製造方法
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
CN104837826B (zh) 2018-07-27
AU2013328929B2 (en) 2018-01-04
US10239858B2 (en) 2019-03-26
PH12015500785B1 (en) 2015-06-15
BR112015008113B1 (pt) 2022-05-24
PL2909188T3 (pl) 2018-08-31
EA030613B1 (ru) 2018-08-31
US20170349569A1 (en) 2017-12-07
BR112015008113A2 (pt) 2017-07-04
US11414396B2 (en) 2022-08-16
CL2015000926A1 (es) 2015-08-28
CN104837826A (zh) 2015-08-12
ZA201502349B (en) 2019-12-18
PE20191818A1 (es) 2019-12-27
HK1213878A1 (zh) 2016-07-15
IN2015DN03928A (uk) 2015-10-02
US20150210668A1 (en) 2015-07-30
CA2889466C (en) 2021-09-14
NZ706723A (en) 2018-07-27
US9771347B2 (en) 2017-09-26
HRP20180670T1 (hr) 2018-07-13
TR201807861T4 (tr) 2018-06-21
EA201590700A1 (ru) 2015-09-30
CN108948043B (zh) 2021-05-04
US20200392104A1 (en) 2020-12-17
MY186549A (en) 2021-07-26
GEP201706690B (en) 2017-06-26
US10793541B2 (en) 2020-10-06
WO2014059422A1 (en) 2014-04-17
CR20200237A (es) 2020-07-26
SI2909188T1 (en) 2018-07-31
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
JP6300042B2 (ja) 2018-03-28
EP2909188A1 (en) 2015-08-26
HK1213567A1 (zh) 2016-07-08
SG11201502795VA (en) 2015-05-28
CN108948043A (zh) 2018-12-07
PE20200387A1 (es) 2020-02-24
JP2018052973A (ja) 2018-04-05
CA2889466A1 (en) 2014-04-17
ES2671502T3 (es) 2018-06-06
CR20150245A (es) 2015-11-19
KR102204520B1 (ko) 2021-01-20
EP2909188B1 (en) 2018-03-07
MX2015004660A (es) 2015-08-07
KR20150067339A (ko) 2015-06-17
MA38085A1 (fr) 2018-08-31
AU2013328929A1 (en) 2015-04-30
SA515360271B1 (ar) 2016-05-19
MX2020005533A (es) 2020-10-12
JP2015533175A (ja) 2015-11-19
PH12015500785A1 (en) 2015-06-15
IL238116B (en) 2018-06-28
PE20151494A1 (es) 2015-11-06

Similar Documents

Publication Publication Date Title
UA115455C2 (uk) Спосіб одержання сполук для застосування при лікуванні раку
MX2019010422A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
UA115176C2 (uk) Інгібітори протеїнкінази
PH12016500225B1 (en) Novel quinoline-substituted compound
MX2015009209A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
MY162933A (en) Chemical compounds
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
MX2014000150A (es) Sistemas, metodos y formulaciones para tratamiento de cancer.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
IN2014DN00123A (uk)
IN2014DN10658A (uk)
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
UA58841U (uk) Спосіб профілактики та оздоровлення поросят
GEP20176633B (en) Use of pidotimod to treat psoriasis